CatalystCorporate
Pelthos Therapeutics stock sinks after Castle Creek merger deal
Pelthos stock fell following its merger deal with Castle Creek.
Context
What happened: Pelthos Therapeutics (PTHS) shares fell after the company agreed to merge with Castle Creek Biosciences (CCBS), expanding its portfolio into cell and gene therapies for serious skin diseases.
Key numbers: Shares fell ~35% to $10.79 on Friday. Castle Creek shareholders will receive 5.2M.
Why it matters: The stock decline followed the announcement of the merger agreement, which moves Pelthos into cell and gene therapies for serious skin diseases.
What changed
Pelthos Therapeutics (PTHS) shares fell after the company agreed to merge with Castle Creek Biosciences (CCBS), expanding its portfolio into cell and gene therapies for serious skin diseases.
Why it matters
The stock decline followed the announcement of the merger agreement, which moves Pelthos into cell and gene therapies for serious skin diseases.
← Dashboard
Oct 30, 2026 02:45 PM ET